Caren Pharma
Developer of hormone-based therapeutics targeting age-related cognitive decline. The company reformulates clinically validated agents and advances proprietary formulations through preclinical studies and streamlined clinical planning aimed at accelerating regulatory filing for neurodegenerative indications.
Industries
Nr. of Employees
small (1-50)
Caren Pharma
Chicago, Illinois, United States, North America
Products
CP001M — Proprietary formulation for Mild Cognitive Impairment (Male)
Program code for a proprietary formulation targeting mild cognitive impairment in males.
CP002F — Proprietary formulation for Mild Cognitive Impairment (Female)
Program code for a proprietary formulation targeting mild cognitive impairment in females.
CP003 — Proprietary formulation for Alzheimer's disease
Program code for a proprietary formulation targeting Alzheimer's disease.
CP004 — Proprietary formulation for Parkinson's disease
Program code for a proprietary formulation targeting Parkinson's disease.
CP005 — Proprietary formulation for Multiple Sclerosis
Program code for a proprietary formulation targeting multiple sclerosis.
CP006 — Proprietary formulation for Adult Depression
Program code for a proprietary formulation targeting adult depression.
CP001M — Proprietary formulation for Mild Cognitive Impairment (Male)
Program code for a proprietary formulation targeting mild cognitive impairment in males.
CP002F — Proprietary formulation for Mild Cognitive Impairment (Female)
Program code for a proprietary formulation targeting mild cognitive impairment in females.
CP003 — Proprietary formulation for Alzheimer's disease
Program code for a proprietary formulation targeting Alzheimer's disease.
CP004 — Proprietary formulation for Parkinson's disease
Program code for a proprietary formulation targeting Parkinson's disease.
CP005 — Proprietary formulation for Multiple Sclerosis
Program code for a proprietary formulation targeting multiple sclerosis.
CP006 — Proprietary formulation for Adult Depression
Program code for a proprietary formulation targeting adult depression.
Expertise Areas
- Hormone-based therapeutic development
- Drug reformulation and repurposing
- Preclinical efficacy and behavioral models
- Preclinical dosing and pharmacology
Key Technologies
- Animal behavioral assays (Morris Water Maze)
- Immunohistochemistry and biomarker quantification
- Formulation development for combination therapies
- Preclinical dosing studies
News & Updates
Company announced a new intellectual property milestone.
Announcement of a proof-of-concept study.
Completion of a preclinical dosing study.
Founding of the company.
Company reported licensing of intellectual property.
Noted start of Dr. Friedman's publications.
Company announced a new intellectual property milestone.
Announcement of a proof-of-concept study.
Completion of a preclinical dosing study.
Founding of the company.
Company reported licensing of intellectual property.
Noted start of Dr. Friedman's publications.